Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role of pharmacogenetics in public health and clinical health care: a SWOT analysis.

Literature DB >> 27577547

Role of pharmacogenetics in public health and clinical health care: a SWOT analysis.

Ritika Kapoor^1,2, Wei Chuen Tan-Koi^2,3, Yik-Ying Teo^1,2,4,5,6.

Abstract

Pharmacogenomics has been lauded as an important innovation in clinical medicine as a result of advances in genomic science. As one of the cornerstones in precision medicine, the vision to determine the right medication in the right dosage for the right treatment with the use of genetic information has not exactly materialised, and few genetic tests have been implemented as the standard of care in health systems worldwide. Here we review the findings from a SWOT analysis to examine the strengths, weaknesses, opportunities and threats around the role of pharmacogenetics in public health and clinical health care, at the micro, meso and macro levels corresponding to the perspectives of the individuals (scientists, patients and physicians), the health-care institutions and the health systems, respectively.

Entities: Species

Mesh：

Year: 2016 PMID： 27577547 PMCID： PMC5117918 DOI： 10.1038/ejhg.2016.114

Source DB: PubMed Journal: Eur J Hum Genet ISSN： 1018-4813 Impact factor: 4.246

54 in total

1. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.

Authors: Laura B Ramsey; Gitte H Bruun; Wenjian Yang; Lisa R Treviño; Selina Vattathil; Paul Scheet; Cheng Cheng; Gary L Rosner; Kathleen M Giacomini; Yiping Fan; Alex Sparreboom; Torben S Mikkelsen; Thomas J Corydon; Ching-Hon Pui; William E Evans; Mary V Relling
Journal: Genome Res Date: 2011-12-06 Impact factor: 9.043

Review 2. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.

Authors: Jacob T Brown; Jeffrey R Bishop
Journal: Pharmacogenomics Date: 2015-08-28 Impact factor: 2.533

3. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.

Authors: A Rauch; D Nolan; A Martin; E McKinnon; C Almeida; Simon Mallal
Journal: Clin Infect Dis Date: 2006-05-26 Impact factor: 9.079

Review 4. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.

Authors: Y Li; H-L Tang; Y-F Hu; H-G Xie
Journal: J Thromb Haemost Date: 2012-02 Impact factor: 5.824

Review 5. Pharmacogenomics knowledge for personalized medicine.

Authors: M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein
Journal: Clin Pharmacol Ther Date: 2012-10 Impact factor: 6.875

6. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.

Authors: Shuen-Iu Hung; Wen-Hung Chung; Zhi-Sheng Liu; Chien-Hsiun Chen; Mo-Song Hsih; Rosaline Chung-yee Hui; Chia-Yu Chu; Yuan-Tsong Chen
Journal: Pharmacogenomics Date: 2010-03 Impact factor: 2.533

7. A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors: Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245

Review 8. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.

Authors: Tong Yin; Toshiyuki Miyata
Journal: Thromb Res Date: 2006-12-11 Impact factor: 3.944

9. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.

Authors: Dyfrig A Hughes; F Javier Vilar; Charlotte C Ward; Ana Alfirevic; B Kevin Park; Munir Pirmohamed
Journal: Pharmacogenetics Date: 2004-06

10. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.

Authors: Kelly E Caudle; Teri E Klein; James M Hoffman; Daniel J Muller; Michelle Whirl-Carrillo; Li Gong; Ellen M McDonagh; Katrin Sangkuhl; Caroline F Thorn; Matthias Schwab; Jose A G Agundez; Robert R Freimuth; Vojtech Huser; Ming Ta Michael Lee; Otito F Iwuchukwu; Kristine R Crews; Stuart A Scott; Mia Wadelius; Jesse J Swen; Rachel F Tyndale; C Michael Stein; Dan Roden; Mary V Relling; Marc S Williams; Samuel G Johnson
Journal: Curr Drug Metab Date: 2014-02 Impact factor: 3.731

12 in total

Review 1. Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy.

Authors: S Harada; Y Zhou; S Duncan; A R Armstead; G M Coshatt; C Dillon; B C Brott; J Willig; J A Alsip; W B Hillegass; N A Limdi
Journal: Clin Pharmacol Ther Date: 2017-06-01 Impact factor: 6.875

2. Assessment of Academic-Community Partnerships in Translational Research.

Authors: Irene Lafarga-Previdi; Carmen M Velez-Vega; Edda I Santiago-Rodriguez; Yolanda Lasalle
Journal: P R Health Sci J Date: 2021-12 Impact factor: 0.705

3. Hypertension Pharmacogenomics in CKD: The Clinical Relevance and Public Health Implications.

Authors: Ting-Ting Geng; Tazeen H Jafar
Journal: Kidney360 Date: 2022-02-24

Review 4. Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity.

Authors: Marleen E Jansen; T Rigter; W Rodenburg; T M C Fleur; E J F Houwink; M Weda; Martina C Cornel
Journal: Front Pharmacol Date: 2017-08-23 Impact factor: 5.810

5. Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx).

Authors: Katja Susanne Just; Michael Steffens; Jesse Joachim Swen; George P Patrinos; Henk-Jan Guchelaar; Julia Carolin Stingl
Journal: Eur J Clin Pharmacol Date: 2017-07-02 Impact factor: 2.953

6. Defining Disease, Diagnosis, and Translational Medicine within a Homeostatic Perturbation Paradigm: The National Institutes of Health Undiagnosed Diseases Program Experience.

Authors: Timothy Gall; Elise Valkanas; Christofer Bello; Thomas Markello; Christopher Adams; William P Bone; Alexander J Brandt; Jennifer M Brazill; Lynn Carmichael; Mariska Davids; Joie Davis; Zoraida Diaz-Perez; David Draper; Jeremy Elson; Elise D Flynn; Rena Godfrey; Catherine Groden; Cheng-Kang Hsieh; Roxanne Fischer; Gretchen A Golas; Jessica Guzman; Yan Huang; Megan S Kane; Elizabeth Lee; Chong Li; Amanda E Links; Valerie Maduro; May Christine V Malicdan; Fayeza S Malik; Michele Nehrebecky; Joun Park; Paul Pemberton; Katherine Schaffer; Dimitre Simeonov; Murat Sincan; Damian Smedley; Zaheer Valivullah; Colleen Wahl; Nicole Washington; Lynne A Wolfe; Karen Xu; Yi Zhu; William A Gahl; Cynthia J Tifft; Camillo Toro; David R Adams; Miao He; Peter N Robinson; Melissa A Haendel; R Grace Zhai; Cornelius F Boerkoel
Journal: Front Med (Lausanne) Date: 2017-05-26

7. Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR.

Authors: Tatjana Huebner; Michael Steffens; Roland Linder; Jochen Fracowiak; Daria Langner; Marco Garling; Felix Falkenberg; Christoph Roethlein; Willy Gomm; Britta Haenisch; Julia Stingl
Journal: BMJ Open Date: 2020-04-27 Impact factor: 2.692